# **A new robust and accurate two-sample Mendelian randomization**

2	method with a large number of genetic variants
3	Lei Zhang <sup>1,2#</sup> *, Jun-Jie Niu <sup>3#</sup> , Xian-Mei He <sup>1</sup> , Xiao Zheng <sup>1</sup> , Qi-Gang Zhao <sup>4</sup> , Xiu-Juan Yu <sup>1</sup> , Li
4	Luo <sup>5</sup> , Hai-Gang Ren <sup>2,6</sup> , Yu-Fang Pei <sup>2,3</sup> *
5	<sup>1</sup> Center for Genetic Epidemiology and Genomics, School of Public Health, Suzhou Medical College
6	of Soochow University, Jiangsu, 215123, PR China.
7	<sup>2</sup> MOE Key Laboratory of Geriatric Diseases and Immunology, Soochow University, Suzhou, Jiangsu
8	215123, PR China.
9	<sup>3</sup> Department of Orthopedic Surgery, the First Affiliated Hospital of Soochow University, Suzhou,
10	Jiangsu, 215006, PR China.
11	<sup>4</sup> Department of Epidemiology and Biostatistics, School of Public Health, Suzhou Medical College of
12	Soochow University, Suzhou, Jiangsu, 215123, PR China.
13	<sup>5</sup> School of Physical Education and Sport Science, Soochow University, Suzhou, 215021, PR China.
14	<sup>6</sup> Laboratory of Molecular Neuropathology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and
15	College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China.
16	#: These authors contributed equally to this work.
17	* Corresponding authors
18	Lei Zhang, Ph. D

- 19 Professor
- 20 Center for Genetic Epidemiology and Genomics

- 21 School of Public Health, Suzhou Medical College of Soochow University
- 22 199 Ren-ai Rd., Suzhou City, Jiangsu Province 215123, PR China
- 23 Tel: (86) 0512-65883871 Email: lzhang6@suda.edu.cn
- 24 Yu-Fang Pei, Ph. D
- 25 Professor
- 26 Department of Epidemiology and Biostatistics
- 27 School of Public Health, Suzhou Medical College of Soochow University
- 28 199 Ren-ai Rd., Suzhou City, Jiangsu Province 215123, PR China
- 29 Tel: (86)0512-65880079 Email: ypei@suda.edu.cn

3	0
_	_

# Abstract

31	Horizontal pleiotropy can significantly confound causal estimates in Mendelian
32	randomization (MR) studies, particularly when numerous instrumental variables (IVs) are
33	employed. In this study we propose a novel statistical method, Mendelian Randomization
34	analysis based on Z-scores (MRZ), to conduct robust and accurate MR analysis in the
35	presence of pleiotropy. MRZ models the IV-outcome association z-score as a mixture
36	distribution, separating the causal effect of the exposure on the outcome from pleiotropic
37	effects specific to each IV. By classifying IVs into distinct categories (valid, uncorrelated
38	pleiotropic, and correlated pleiotropic), MRZ constructs a likelihood function to estimate
39	both causal and pleiotropic effects. Simulation studies demonstrate MRZ's robustness, power,
40	and accuracy in identifying causal effects under diverse pleiotropic scenarios and overlapped
41	samples. In a bidirectional MR analysis of appendicular lean mass (ALM) and four lipid
42	traits using both the UK Biobank (UKB)-internal datasets and the UKB-Global Lipids
43	Genetics Consortium (GLGC) joint datasets, MRZ consistently identified a causal effect of
44	ALM on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). Conversely,
45	existing methods often detected mutual causal relationship between lipid traits and ALM,
46	highlighting their susceptibility to confounding by horizontal pleiotropy. A randomized
47	controlled experiment conducted in mice validated the absence of causal effect of TC on
48	ALM, corroborating the MRZ findings and further emphasizing its resilience against
49	pleiotropic biases.

50 Keywords: Mendelian randomization; uncorrelated pleiotropy; correlated pleiotropy;
51 appendicular lean mass; lipid traits.

-	2
7	/
-	-

### Introduction

53	Determining whether a modifiable exposure causes a particular disease outcome is
54	crucial for understanding disease mechanisms and guiding prevention and clinical
55	interventions. However, traditional observational analyses often face limitations in
56	establishing such causal effects due to potential confounding by unobserved variables or
57	reverse causation [1]. Mendelian randomization (MR) provides a solution by offering a
58	statistical approach to infer causation from observational data while circumventing both
59	unobserved confounding and reverse causation [1, 2]. MR utilizes genetic variation associated
60	with an exposure as an instrumental variable (IV) to investigate the causal effect of the
61	exposure on an outcome [2].
62	MR has proven highly successful in uncovering causal relationships across a wide range
63	of epidemiological conditions and diseases, establishing itself as a popular approach in
64	modern genetic epidemiology [3]. The rapid growth of genome-wide association studies
65	(GWASs) further accelerates the application of MR by providing a wealth of data. With larger
66	sample sizes, modern GWASs generate numerous IVs suitable for MR analysis. For instance,
67	the latest human height GWAS identified over 11,000 independent association signals [4],
68	enhancing the power and accuracy of MR estimation.

However, many current MR analyses are challenged by a potentially severe confounding factor known as horizontal pleiotropy [5]. Horizontal pleiotropy violates the exclusive restriction assumption underlying the MR principle, casting doubt on the validity of MR analysis [6-8]. This issue becomes more pronounced as the number of IVs increases, as chance can lead to an increase in shared heritability factors between exposure and outcome.

74 Therefore, effective correction for confounding due to horizontal pleiotropy is essential,

75 especially in large sample settings.

Considerable efforts in the literature have addressed the pleiotropic effect and sought to mitigate its adverse impact on MR analysis [9, 10]. In a two-sample setting, multiple popular statistical methods accommodating pleiotropic IVs have been proposed and widely utilized [11-37]. However, under certain conditions, some methods may fail to adequately correct for horizontal pleiotropy or accurately detect true causal effects [9].

81 In this study, with the aim of conducting robust and accurate MR studies in the presence 82 of horizontal pleiotropy, we introduce a novel statistical method. This method explicitly 83 distinguishes causal effect from pleiotropic effect and estimates both within the maximum 84 likelihood framework. Through simulation studies, we demonstrate that our proposed method 85 effectively corrects for pleiotropic effects across various confounding scenarios while 86 maintaining statistical power at a comparable level. As an application, we investigate the 87 bidirectional causal effects of four lipid traits and appendicular lean mass (ALM) using data 88 from the UK biobank (UKB) cohort and summary statistics from the Global Lipids Genetics 89 Consortium (GLGC) [38]. Finally, we conduct a randomized controlled experiment in mice to 90 address controversial findings revealed by our proposed method compared to alternative 91 methods.

5

92

## Results

# 93 Outline of the proposed method

94	The diagram illustrating the proposed method is presented in <b>Figure 1</b> . In this context,
95	we consider the causal effect, denoted as $r$ , of a continuous exposure trait $X$ on a continuous
96	outcome trait Y. Our objective is to estimate this causal effect using a collection of
97	independent IVs that exhibit an association with $X$ . These IVs are categorized into three
98	distinct types based on their pleiotropic effects on the outcome and the correlation of these
99	pleiotropic effects with the IV-exposure effects at corresponding IVs:
100	1. Valid IVs: These IVs do not exert horizontal pleiotropic effects on the outcome. They
101	serve as reliable indicators of the exposure's effect on the outcome without introducing
102	additional confounding factors.
103	2. Uncorrelated pleiotropic IVs: This category comprises IVs that exhibit horizontal
104	pleiotropic effects on the outcome. However, these effects are not correlated with the
105	corresponding IV-exposure effects.
106	3. Correlated pleiotropic IVs: In this category, IVs demonstrate horizontal pleiotropic effects
107	on the outcome that are correlated with the IV-exposure effects. This correlation violates the
108	Instrument Strength Independent of Direct Effect (INSIDE) assumption [39].
109	In our analysis, we used genetic association z-scores, denoted as $z_X$ and $z_Y$ , to estimate $r$ .
110	The outcome $z_Y$ follows a normal distribution with a mean $\mu_Y$ and a variance of one,
111	i.e., $z_Y \sim N(\mu_Y, 1)$ , where $\mu_Y$ represents the effect of the IV on the outcome. The causal
112	effect of X on Y can be interpreted as shifting the mean $\mu_Y$ by an IV-specific offset denoted
113	as $\Delta = \sqrt{\frac{N_Y}{N_X}} \times r z_X$ , where $N_X$ and $N_Y$ are the sample sizes of the exposure and outcome,

respectively. Importantly, this shift applies uniformly across all IVs regardless of whether
they are valid or pleiotropic. Consequently, if we subtract this offset Δ from z<sub>Y</sub>, we obtain a
residual z-score z'<sub>Y</sub> = z<sub>Y</sub> - Δ. This residual z-score no longer contains any information
about the causal effect.
We formulated z'<sub>Y</sub> at different types of IVs to follow distinct distributions.
Valid IVs: z'<sub>Y</sub> at valid IVs asymptotically follows a standard normal distribution, i.e.,

120 
$$Z'_{Y \text{ valid}} \sim N(0, 1).$$

121 2. Uncorrelated pleiotropic IVs: At uncorrelated pleiotropic IVs,  $z'_{Y}$  follows a normal

122 distribution with a fixed mean parameter  $\mu_1$  and an enlarged variance, i.e.,

$$z'_{Y,\text{unc}} \sim N(\mu_1, 1 + \sigma_{eu}^2)$$

123 , where  $\mu_1$  and  $\sigma_{eu}^2$  represent the mean and variance of the uncorrelated pleiotropic effects, 124 respectively.

3. Correlated pleiotropic IVs: $z'_{Y}$  at correlated pleiotropic IVs follows another normal distribution. This distribution is characterized by a mean parameter related to  $z_{X}$  and an enlarged variance, i.e.,

$$z'_{Y,cor} \sim N(\mu_2 + \mu_a z_X, 1 + z_X^2 \sigma_a^2 + \sigma_{ec}^2)$$

128 , where  $\mu_a$  and  $\sigma_a^2$  represent the mean and variance of the pleiotropic correlation, 129 respectively.  $\mu_2$  and  $\sigma_{ec}^2$  represent the mean and variance of the residual pleiotropic effects 130 after adjusting for the pleiotropic correlation.

These formulations allow us to account for the different distributions of residual
z-scores at various types of IVs, thereby capturing the distinct effects of horizontal
pleiotropy on the outcome.

134 Given the presence of multiple independent IVs, we employed the maximum likelihood 135 approach to estimate the parameters from the data. We assumed that the proportions of valid 136 IVs, uncorrelated pleiotropic IVs, and correlated pleiotropic IVs are  $(1-\tau)$ ,  $\tau(1-\rho)$ , and  $\tau\rho$ , 137 respectively. Here,  $\tau$  and  $\rho$ , both fallowing within the range [0,1], represent the proportion 138 of total pleiotropic IVs and the relative proportion of correlated pleiotropic IVs, respectively. Our model contains nine parameters in total:  $\theta = (r, \mu_1, \mu_2, \mu_a, \sigma_{eu}^2, \sigma_{ec}^2, \sigma_a^2, \tau, \rho)$ . We 139 140 constructed a likelihood function of  $\theta$  as follows 141  $L(\mathbf{0}; \mathbf{z}_{X}, \mathbf{z}_{Y}, \mathbf{N}_{X}, \mathbf{N}_{Y}) = \prod_{m=1}^{M} \{ (1-\tau) P_{\text{valid}}(z'_{Ym}) + \tau (1-\rho) P_{\text{unc}}(z'_{Ym} | \mu_{1}, \sigma_{eu}^{2}) + \tau \rho P_{\text{cor}}(z'_{Ym} | \mu_{a}, \mu_{2}, \sigma_{a}^{2}, \sigma_{ec}^{2}) \}.$ 142 Maximizing L with respect to  $\boldsymbol{\theta}$  provides the maximum likelihood estimate of  $\boldsymbol{\theta}$ . 143 From this estimate, we can derive both the estimated causal effect, denoted as  $\hat{r}$ , and the 144 distribution of pleiotropic effects. 145 To assess the statistical significance of the estimates, we employed the likelihood ratio 146 test (LRT) approach. Specifically, we examined the significance of  $\hat{r}$  using a 147 one-degree-of-freedom (df) chi-squared test. This test compares the maximized likelihood 148 value with that obtained for a reduced likelihood function under the setting r=0. Additionally, 149 we evaluated the existence of pleiotropic IVs using an 8-df chi-squared test. This test 150 compares the maximized likelihood value with that obtained for another reduced likelihood 151 function under the setting  $\tau=0$ , in which r is the only model parameter. 152 The distribution of  $z'_{Y}$ 

The distribution of  $z'_{Y}$  is central to our proposed method, <u>Mendelian Randomization</u> analysis using <u>Z</u>-scores (MRZ), as it forms the basis for distinguishing between valid and pleiotropic IVs. Among the two parameters shaping the distribution of  $z'_{Y}$ , variance plays a

156 crucial role in distinguishing between these categories. Through simulations, we investigated 157 the distribution of  $z'_{Y}$  and evaluated the impact of three key factors on its variance: the sample size of the outcome  $(N_Y)$ , the variance  $(\sigma_h^2)$  of the pleiotropic effect  $h_Y^2$ , and the 158 frequency of positive pleiotropic IVs  $(f_p)$ . Here,  $h_Y^2$  was defined as the IV-attributable 159 portion of outcome variance, that is, IV-specific outcome heritability. As expected,  $z'_{Y}$  at 160 161 valid IVs consistently conforms to a standard normal distribution (Figure 2). Conversely, at pleiotropic IVs, the variance of  $z'_Y$  exceeds one and escalates with increasing  $N_Y$  and/or  $\sigma_h^2$ . 162 163 Specifically, when all pleiotropic IVs align in the same direction as the IV-exposure effects  $(f_p=1)$ , the variance of  $z'_Y$  aligns well with theoretical expectations, which is  $var(\sqrt{N_Y \Box_Y^2})$ . 164 165 This variance amplifies when pleiotropic IVs consist of a mixture of positive and negative 166 effects, reaching its maximum when the positive and negative pleiotropic IVs are evenly 167 balanced ( $f_p=0.5$ ).

168 Our simulations also revealed a striking resemblance between the distributions of  $z'_{Y}$ 169 and  $z_{Y}$ . This similarity arises from the positive nature of all  $z_{X}$  by definition, leading to a consistent shift of  $z_Y$  towards  $z'_Y$  in the same direction across all IVs. Another fact 170 171 reinforcing this similarity is the typically modest magnitude of the shift  $\Delta$ , attributed to the 172 small values of r in most real applications (e.g., <0.2). Consequently, we approximated the variance of  $z'_Y$  by studying  $z_Y$  as if no causal effect were present. By assuming an 173 174 exponential distribution for pleiotropic effects, we estimated the distribution's sole parameter [40]. Subsequently, we estimated the variance of  $z'_{Y}$  through Monto-Carlo 175 sampling of  $\sqrt{N_Y h_Y^2}$ . While this estimate assumes all pleiotropic effects align in the same 176 177 direction and may thus underestimate the true variance, it provides a practical lower 178 boundary from which the optimization of the likelihood function starts to work.

### **179 Detecting pleiotropic effects**

180	When all IVs are valid, MRZ does not detect any pleiotropy in both null and causal
181	simulations ( $P < 0.05$ ). Notably, it is more conservative than MRPRESSO [19] and
182	MREGGER [22], both of which identify pleiotropy and horizontal pleiotropy in
183	approximately 5% of iterations.

In scenarios where pleiotropic IVs are present, both MRZ and MRPRESSO demonstrate remarkable efficacy, presenting 100% power in detecting pleiotropy even when the proportion of pleiotropic IVs is as low as 10% (**Figure 3A**). Conversely, MREGGER exhibits significantly lower power in discerning the directionality of pleiotropic effects. Even at the highest proportion (60%), MR-EGGER's power rate is only 55.5%.

The proportion of pleiotropic IVs estimated by MRZ exhibits a high correlation with the actual proportion, irrespective of the presence of a causal effect or the correlation status of pleiotropic effects (**Figure 3B**). However, a slight overestimate of the mean proportion by a relative proportion of approximately 10% is observed across all scenarios.

In instances where correlated pleiotropic IVs are present, MRZ's ability to accurately estimate their proportion is unsatisfactory (**Figure 3C**). This suggests that uncorrelated and correlated pleiotropic IVs are indistinguishable by MRZ. Nevertheless, the per-IV mean correlated pleiotropic effect, defined as  $\tau\rho\mu_a$ , exhibits a perfect linear relationship with the proportion of correlated pleiotropic IVs (**Figure 3D**). The slope of this linear trend remains consistent between null and causal simulations, indicating minimal influence of the causal effect on the trend. Furthermore, the slope increases with stronger correlated pleiotropic

200 effects and diminishes when no correlated pleiotropic IVs are included. Therefore, MRZ

- 201 demonstrates the capability to capture correlated pleiotropic effects by jointly modeling the
- 202 proportion of correlated pleiotropic IVs and the magnitudes of their effects.
- 203 Causal effect: type-I error rate

204 Through a series of null simulations, we evaluated the type-I error rate of MRZ in 205 testing causal effect. For comparative purposes, we incorporated 14 existing two-sample MR 206 methods into our analysis. These include MREGGER [22], IVW [23], weighted-median 207 (W-median) [21], weighted-mode (W-mode) [20], MRPRESSO [19], contamination mixture 208 (CMix) [16], MRMix [18], MRAID [11], MRcML [12], GRAPPLE [13], MRLASSO [17], 209 MRRAPS [14], MRROBUST [17], and CAUSE [15]. It's worth noting that there are other 210 promising methods not included in our analysis, some of which are extensively discussed 211 elsewhere [9].

In the absence of pleiotropic effects, MRZ, along with other methods, effectively maintains type-I error rates close to the desired level of 5% (**Table 1**). However, W-mode (0.2%) and CAUSE (0.1%) demonstrate conservativeness, exhibiting lower type-I error rates.

In scenarios where pleiotropic effects are present, MRZ consistently maintains the correct type-I error rate across various proportions of pleiotropic IVs, irrespective of whether the pleiotropic effects are uncorrelated or correlated (**Table 2**). This robust performance also holds true under balanced pleiotropic effects (**Supplemental Table 1**). Among alternative methods, W-mode and CAUSE tend to be overly conservative, resulting in significantly reduced type-I error rates in all scenarios (**Table 2**). MREGGER shows

222 validity only when pleiotropic effects are uncorrelated but exhibits an inflated type-I error 223 rate of up to 28.1% when the pleiotropic effects are correlated. MRMix generally performs 224 well under low to modest proportions of pleiotropic IVs but shows an inflated error rate 225 reaching up to 21.6% under higher proportions. All the other alternative methods have 226 inflated type-I error rates that increase with increased proportion of pleiotropic IVs, whereas 227 the inflation is more severe under correlated pleiotropy than under uncorrelated pleiotropy. 228 The type-I error rates for certain methods can reach nearly 100% in some extreme scenarios, 229 rendering them invalid at all under such conditions. Even when the pleiotropic effects are 230 balanced, the inflation of type-I error rates is still observed for most alternative methods, 231 especially in correlated pleiotropic scenarios (Supplemental Table 1). 232 Further simulation studies involving a smaller set of 100 IVs (Supplemental Table 2) 233 or a larger set of 500 IVs (Supplemental Table 3) reaffirm the validity of MRZ. Among 234 alternative methods, W-mode and CAUSE exhibit inflated type-I error rates under high

proportions of pleiotropic IVs when the number of IVs is 100 and 500, respectively,
rendering them invalid (Supplemental Tables 2-3). Therefore, our simulations reveal
MRZ's efficacy in rectifying horizontal pleiotropy across diverse confounding scenarios,
where existing methods often lose validity.

Notably, MRZ demonstrates strong robustness against sample overlap due to its effective control of horizontal pleiotropy. It maintains a valid type-I error rate even when exposure and outcome samples completely overlap (**Supplemental Table 4**), making it suitable for scenarios involving a single biobank-scale dataset such as the UKB cohort.

243 Causal effect: power and effect size

12

244	We conducted a series of causal simulations to examine the power and effect size of
245	various methods. In scenarios without pleiotropic effects, nearly all alternative liberal
246	methods-those prone to type-I error under pleiotropic scenarios-demonstrate remarkably
247	high power rates almost reaching 100% (Table 1). MRZ notably achieves a power rate of
248	99.9%, positioning it among the most powerful methods. Conversely, W-mode exhibits the
249	lowest power rate (10.4%), followed by MRMix (25.9%) and CAUSE (80.0%). Regarding
250	effect size estimation, most methods, including MRZ, estimate mean effect sizes close to the
251	true value of 0.050. MRZ displays one of the lowest mean errors (MEs, 0.008) among all
252	methods. In contrast, W-mode (0.033) and MRMix (0.025) exhibit larger variations.
253	In the presence of horizontal pleiotropy, MRZ exhibits a decline in power as the
254	proportion of pleiotropic IVs increases, as expected. This decline is similar in both positive
255	and negative causal effect settings (Supplemental Table 5), indicating minimal impact of
256	pleiotropic effects on MRZ's power across diverse scenarios. Even with the highest
257	proportion of 60% pleiotropic IVs, MRZ's power rate maintains between 40%-58%.
258	Alternative methods demonstrate scenario-dependent performance, lacking a universal
259	trend across all settings. The two overly conservative methods CAUSE and W-mode, along
260	with MREGGER, MRMix and MRAID, generally exhibit declining power with increased
261	proportion of pleiotropic IVs (Supplemental Table 5). For other alternative methods, two
262	distinct trends are observed depending on the relative directions of the causal effect and the
263	pleiotropic effects. When they align, these methods maintain high power rates at nearly 100%
264	at all proportions of pleiotropic IVs. Conversely, when they oppose, these methods
265	experience rapid decline in power rates with increased proportion of pleiotropic IVs

266 (Supplemental Table 5). These conflicting trends highlight potential confounding effects of

267 uncorrected pleiotropy on power estimation.

268 To ensure a fair comparison of power rates among methods despite varying type-I error 269 rates, we corrected each method's raw power rate by its type-I error rate at the corresponding 270 null setting, assuming a correct type-I error rate of 5%. Like MRZ, all alternative methods 271 have a decrease in their corrected power rates when the proportion of pleiotropic IVs 272 increases (Figure 4). Among the methods, MRZ generally maintains the highest corrected 273 power rate across various proportions of pleiotropic IVs. This improvement is particularly 274 notable when the causal effect opposes the pleiotropic effects, in which cases uncorrected 275 pleiotropic effects counteract or even reverse the true causal effect, resulting in a severe loss 276 of power for alternative methods.

277 Uncorrected pleiotropic effects not only affect the power to detect the causal effect but 278 also influence estimated effect size. MRZ's estimated effect sizes align with the true value 279 (0.05 or -0.05) across all scenarios (Figure 5), regardless of the proportion of pleiotropic IVs 280 or the direction of the causal effect. Conversely, for all alternative methods, including 281 W-mode and CAUSE, distinct trends are observed based on the relative directions of the 282 causal effect to pleiotropic effects. When the directions align, mean effect sizes of all 283 alternative methods tend to increase with the proportion of pleiotropic IVs, whereas they 284 decrease when the directions oppose. At the highest proportion of 60% pleiotropic IVs, the 285 decrease is so severe that the estimated effect sizes from all alternative methods are opposite 286 to the true size.

Additional simulation studies with 100 and 500 IVs (Supplemental Figure 1) reveal an

increased trend of MRZ's power rate with an increasing number of IVs, underscoring the
critical importance of including a substantial number of IVs for robust and powerful causal
inference.

When modeling no pleiotropic effects, the proposed test statistic  $T_1$  closely approximates the causal effect size estimated by the IVW test across all simulated scenarios (**Supplemental Figure 2**). This suggests that the IVW test provides a reasonable anchor for MRZ to adjust its estimated effect size when analyzing un-standardized summary statistics, such as case-control data.

296 **Running time** 

297 The computation process of MRZ primarily focuses on optimizing the likelihood 298 function twice: once for the alternative hypothesis and once for the null hypothesis. Despite 299 involving a high dimension of nine parameters, the derivative-free optimization algorithm 300 *nmkb* that we employed offers an efficient solution. MRZ completes the optimization within 301 seconds even on datasets containing 500 IVs. However, it's important to acknowledge that 302 there is no assurance that the optimization algorithm will converge to its global maximum 303 under such a high-dimensional parameter space. Therefore, it's recommended to conduct 304 repeated optimizations with varying initial parameter settings to enhance the likelihood of 305 obtaining a robust solution. In this study, a total of 20 repeats were performed to ensure the 306 reliability of the results.

307 Real data analysis

As an application, we conducted a bidirectional MR study examining the relationship
between ALM and four circulating lipid traits (high-density lipoprotein cholesterol (HDL-C),

15

310 low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG)).

We utilized two data sources: the UKB internal cohort and the summary statistics releasedby GLGC.

313 In the UKB-internal analysis, we randomly divided the entire UKB cohort into two 314 independent sub-samples (UKB\_S1 and UKB\_S2). For each exposure-outcome pair (e.g., 315 ALM-TC), one sub-sample served as the exposure sample while the other served as the 316 outcome sample. This process was repeated twice by reversing the roles of the two 317 sub-samples so that two independent sets of summary statistics were generated [41]. In the 318 UKB-GLGC joint analysis, we used the entire UKB cohort to generate GWAS summary 319 statistics for ALM, while GLGC data (excluding UKB participants) provided summary 320 statistics for the lipid traits. Consequently, we generated three datasets that are mutually 321 independent in exposure and/or outcome, allowing for cross-validation of results.

- To assess robustness against sample overlap, we conducted an MR analysis using both exposure and outcome summary statistics derived from the entire UKB cohort, resulting in complete sample overlap.
- Observational analyses reveal significant correlations between raw ALM values and all lipid traits in the UKB cohort, and these correlations persist after adjusting for age and sex in both ALM and lipid traits (**Supplemental Table 6**). In the MR settings, the number of eligible IVs ranges from 85 to 719 across all exposure-outcome pairs (**Supplemental Tables 7-8**). Strong IV-exposure associations are observed, with  $R^2$  values ranging from 0.05 to 0.10 and *F*-statistics ranging from 52.1 to 188.8.

331	At a significance level of $6.25 \times 10^{-3}$ (0.05/(2×4)), forward MRZ analysis identified a
332	negative association between ALM and both TC and LDL-C (Table 3). This association is
333	statistically significant in all three datasets for both traits, strengthening the evidence of
334	causality. The estimated effect sizes are consistent across datasets for both TC (-0.079,
335	-0.083 and -0.074) and LDL-C (-0.054, -0.063 and -0.037). Notably, the proportion of
336	pleiotropic IVs was estimated to be modest to high for both traits, being around 30% and 40%
337	in the UKB-internal datasets (261-268 IVs).

Forward MR analyses using MRZ did not detect significant associations between ALM and either HDL-C or TG in any of the datasets, suggesting no causal effects on both traits. Further reverse MR analyses did not identify significant associations for any lipid traits with ALM, indicating no reverse causal effect. Analysis on the completely overlapped whole UKB cohort yielded similar results (**Supplemental Table 9**), confirming MRZ's robustness against sample overlap.

344 We compared the MRZ results with those from alternative methods. In the forward MR 345 analyses, all alternative methods identified the same negative causal effect of ALM on TC in 346 one or more datasets (Supplemental Figure 3). However, in the reverse MR analyses, all 347 alternative methods revealed a same negative causal effect of TC on ALM in at least one 348 dataset (Supplemental Figure 3). The results of mutual causality at the same direction are 349 observed from alternative methods on the other three lipid traits too (Supplemental Figures 350 **4-6**). Observing mutually reinforcing causal effects at the same direction suggests a high 351 likelihood of pleiotropy, making it difficult to definitively determine the true causal relationship. Therefore, leaving aside the true causal relationships, none of the alternative 352

353 methods can produce results that are free of pleiotropic effects and that are self-validated

across all datasets.

### 355 Experimental validation

356 Given the unidirectional causal link identified by MRZ versus the disputed 357 bidirectional link suggested by alternative methods, there are conflicting views on the causal 358 effect of lipid traits on ALM. To address this controversy empirically, we conducted an in 359 vivo randomized controlled experiment using a mouse model. The experiments involved 360 intervention with TC and compared to normal controls. The results reveal a significant 361 increase in circulating TC levels in mice fed TC for a period of 8 weeks (N=12) compared to normal controls (N=12, Wilcoxon rank test  $P=3.59\times10^{-5}$ , Figure 6), indicating successful 362 363 implementation of the TC intervention. Additionally, significant changes are observed in HDL-C ( $P=1.24 \times 10^{-14}$ ), LDL-C ( $P=5.98 \times 10^{-9}$ ), and TG ( $P=5.98 \times 10^{-5}$ ) levels. 364

As the outcome, we observed a significant increase in total body mass ( $P=1.64\times10^{-3}$ ) and fat body mass ( $P=1.03\times10^{-4}$ ) in the TC intervention group. However, there is no significant difference in lean body mass (P=0.80), suggesting no causal effect of lipid traits on ALM. These findings are consistent with the results obtained from MRZ analyses, but differ from the conclusions drawn by most alternative methods. This highlights MRZ's resilience against horizontal pleiotropic effects, to which existing methods are more susceptible.

2	-	2
3	1	2

# Discussion

373	Under the prevailing polygenic genetic architecture of complex traits, pleiotropy is
374	anticipated to be a common occurrence [42]. While theoretical assertions suggest that
375	perfectly balanced pleiotropic effects could cancel out bias [22], achieving such equilibrium
376	is impractical. Current MR practices often employ sensitivity analyses like the MREGGER
377	intercept test to evaluate pleiotropy balance [22]. However, our simulation studies revealed
378	that the MREGGER intercept test lacks sufficient power to detect even substantial
379	pleiotropic imbalances. Thus, relying solely on these methods cannot ensure that empirical
380	MR analyses are conducted under balanced pleiotropic conditions. Even under balanced
381	pleiotropy, our simulation studies demonstrated that the type-I error rate of certain methods
382	may inflate as the proportion of pleiotropic IVs increases. The presence of correlated
383	pleiotropic effects exacerbates this issue. Therefore, robust methods to address horizontal
384	pleiotropy are crucial to ensure the validity of MR analyses.
385	Our proposed method, MRZ, categorizes IVs into three distinct groups reflecting
386	potential pathways from IVs to the outcome, as depicted in the classical MR rationale
387	diagram. By assuming a general normality distribution for underlying pleiotropic effects, we
388	derived a precise distribution for IV-outcome z-scores specific to each category. In simulated
389	scenarios encompassing diverse pleiotropic settings, MRZ demonstrates enhanced control of
390	type-I error rate as well as more precise and powerful causal effect estimation than existing
391	methods. Notably, the normality assumption assumed by MRZ was not met in our

392 simulations. However, we did not observe inflated type-I error rates or imprecise effect

393 estimates, demonstrating the robustness of MRZ against data distribution.

394	Multiple sophisticated models have been proposed to address horizontal pleiotropy in
395	MR analyses, with some examples provided in this study. While these methods demonstrate
396	excellent performance under specific conditions, our simulation studies reveal limitations
397	when the number of IVs reaches the hundreds. In such scenarios, certain alternative methods
398	struggle to effectively correct for pleiotropic effects. This challenge arises because
399	pleiotropic effects are often systematic, meaning they are not simply averaged out with an
400	increasing number of IVs. In fact, the presence of systematic pleiotropy can worsen as the
401	number of IVs grows.
402	Among alternative methods, MRMix shares a similar strategy of categorizing IVs based
403	on their potential causal effects [18]. However, MRMix utilizes four categories reflecting all
404	combinations of the presence or absence of direct effects between IVs and both the exposure
405	and the outcome. This classification allows MRMix to include IVs with no association to the
406	exposure. In contrast, MRZ assumes all IVs to be associated with the exposure, aligning
407	with the standard practice of screening and filtering IVs in empirical MR analyses to ensure
408	this condition.

Another key distinction between MRZ and MRMix lies in the data modeling strategy. MRMix assumes both IV-exposure and IV-outcome effects are random variables following a bivariate normal distribution. Conversely, MRZ treats the IV-exposure effect as a fixed value and models only the IV-outcome effect as a random variable with a distribution conditional on the former. This approach in MRZ eliminates the requirement for a normality assumption on the IV-exposure effect, making it more robust to non-normality, a frequent characteristic in non-infinitesimal genetic models.

416	Another comparable method, CMix, employs distinct probability functions to model
417	valid and pleiotropic IVs as well. Key disparities between MRZ and CMix include the
418	following: 1) MRZ categorizes pleiotropic IVs into uncorrelated and correlated groups,
419	offering a more detailed classification compared to CMix, which treats all pleiotropic IVs
420	collectively; 2) Both methods assume a normal distribution for effect sizes of pleiotropic IVs.
421	However, MRZ allows the mean parameter of this distribution to vary freely, while CMix
422	constrains it to zero but allows for an expanded variance; 3) MRZ integrates uncertainty
423	regarding IV validity into its likelihood function without explicitly designating each IV as
424	valid or pleiotropic. Conversely, CMix explicitly assigns a label to each IV based on its
425	estimated probability of being valid or pleiotropic under each parameter setting. We argue
426	that incorporating IV uncertainty may provide valuable insights into the distribution of
427	pleiotropic IVs. Our simulation studies demonstrate that MRZ can effectively estimate the
428	proportion of pleiotropic IVs, thereby supporting its efficacy.
429	Skeletal muscle and circulating lipids play a critical role in regulating energy balance
430	[43-45]. They are intricately linked and share common genetic background [46, 47]. Our real
431	data analysis revealed a high degree of pleiotropy between ALM and all the lipid traits we
432	examined. This pleiotropy poses a significant challenge for most existing MR methods.

437 different result that aligned with the experiment results. This highlights the importance of

433

434

435

436

These methods tend to have inflated type-I error rates when the proportion of pleiotropic IVs

is modest to high. As evidence, all alternative methods discovered a causal effect of TC on

ALM in at least one dataset. However, this finding contradicted the results of controlled

experiments where TC levels were directly manipulated. In contrast, MRZ yielded a

robust methods for accurate causal inference in MR studies, especially when pleiotropy is amajor concern.

440	The observed causal effect of ALM on TC and LDL-C in our real data analysis is
441	supported by nearly all alternative methods. Several plausible biological mechanisms could
442	underlie this causality: 1) Metabolic rate and energy balance: Lean mass contributes
443	significantly to basal metabolic rate [48, 49], which in turn can influence lipid metabolism
444	and cholesterol levels. 2) Insulin sensitivity: Muscle tissue plays a crucial role in glucose
445	metabolism and insulin sensitivity [50]. Higher lean mass is often associated with improved
446	insulin sensitivity and glucose uptake [50], which in turn lead to changes in TC and LDL-C
447	levels [51]; 3) Anti-inflammatory effects of muscle: Muscle secretes beneficial hormones
448	such as interleukin-6 (IL-6) and irisin [52, 53], which have anti-inflammatory properties.
449	These hormones can influence lipid metabolism and cholesterol levels [54, 55].
450	It should be notable that ALM is usually altered by other modifiable factors such as
451	exercise and diet. In this case, they are in the same causal pathway, and it is unclear whether
452	the changes in circulating TC and LDL-C are directly caused by changes in ALM or if ALM
453	acts as a mediator of some modifiable factor. Further investigation is warranted to elucidate
454	the biological mechanism underlying this causal relationship.
455	Certain limitations exist in the proposed method. Firstly, it does not account for certain
456	biases common in MR analyses, such as weak instrument bias [56] and winner's curse bias
457	[57]. These biases can potentially be mitigated by implementing stringent IV filtering, such
458	as applying a more rigorous significance threshold [57]. Secondly, optimizing a

459 high-dimensional likelihood function poses challenges in converging to its global solution.

460 To enhance the likelihood of reaching the global maximum, it is advisable to perform 461 multiple optimizations with varying initial parameters. However, this approach increases 462 computational burden and does not guarantee attainment of the global maximum. Thirdly, 463 the proposed method requires both exposure and outcome sample sizes as input, unlike other 464 methods that do not have this requirement. This necessity arises because z-scores are 465 meaningful only within the context of a specific sample size. If exposure and outcome 466 sample sizes are uniform so that their ratios are constant across all IVs, then the detailed 467 sample sizes are indeed unnecessary because the estimated effect size remains unchanged 468 after calibrating to the effect size estimated by the IVW test. However, if sample sizes vary 469 across IVs, then providing this information is essential for unbiased estimation by the 470 proposed method. Furthermore, in scenarios involving case-control studies with imbalanced 471 case-to-control ratios, employing an effective sample size rather than a raw sample size is 472 preferable for accurate estimation [58].

473 In summary, we have proposed a novel two-sample MR method that demonstrates 474 robustness against horizontal pleiotropic effects, while also offering accuracy and power 475 across a wide range of scenarios. By applying this method to investigate the relationship 476 between ALM and lipid traits, we identified a negative causal effect of ALM on TC and 477 LDL-C. Our proposed method serves as a valuable alternative to existing MR methods, 478 particularly in the analysis of large-scale biobank datasets with numerous IVs. With its 479 ability to provide reliable and precise causal inference, our method contributes to advancing 480 the field of MR analysis and enhances our understanding of complex biological 481 relationships.

### Online methods

#### 483 Basic model

482

We assumed a continuous exposure trait X, a continuous outcome trait Y, and a bi-allelic SNP G taking values between 0, 1, and 2. For ease of presentation, we assumed Xand Y are standardized so that their variances are one. Assumed that G is associated with Xand serves as its IV and that the associations of G with both X and Y were tested under an additive mode of inheritance.

489 The basic phenotype model for MR analysis was formulated as following

$$490 X = \beta_1 G + \varepsilon_X,$$

$$Y = rX + \varepsilon_Y = (r\beta_1)G + \varepsilon'_Y$$

491 , where  $\beta_1$  measures the effect of *G* on *X*, *r* measures the causal effect of *X* on *Y*, and  $\varepsilon_X$ 492 and  $\varepsilon_Y$  ( $\varepsilon'_Y$ ) are independently and normally distributed random errors. Here, we used the 493 term *r* for a causal effect of *X* on *Y* because it is equivalent to the correlation coefficient for 494 two standardized phenotypes.

In the above model, the parameter *r* is the focus of MR analysis. In a typical two-sample MR analysis, regression coefficients of both *X* and *Y* on *G* are available from GWAS analyses, denoted by  $\hat{\beta}_1$  and  $\hat{\beta}_G^Y$ . Then an unbiased estimator of *r* would be [23]

 $\hat{r} = \frac{\hat{\beta}_G^Y}{\hat{\beta}_1}.$ 

Below, we modeled the estimation problem using the genetic association z-score, which

500 is defined as the regression coefficient divided by its standard error. Specifically,

501 
$$z_X = \frac{\hat{\beta}_1}{\hat{\sigma}_1}$$
, and  $z_Y = \frac{\hat{\beta}_G^Y}{\hat{\sigma}_G^Y}$ 

502 , where  $\hat{\sigma}_1$  and  $\hat{\sigma}_G^Y$  are standard errors of  $\hat{\beta}_1$  and  $\hat{\beta}_G^Y$ .

The squared *z*-score statistic, termed  $s_X$  or  $s_Y$ , is commonly used to test the genetic association between *G* and *X* or *Y*. When there is no association, the *s* statistic asymptotically follows a 1-df central chi-squared distribution. Accordingly, the *z*-score asymptotically follows a standard normal distribution. In contrast, when genetic association exists, the *s* statistic asymptotically follows a 1-df non-central chi-squared distribution characterized by a non-central parameter (NCP)  $\lambda$ , and the *z*-score asymptotically follows a normal distribution with variance one but with a non-zero mean parameter  $\mu$  where  $\mu^2 = \lambda$ , i.e.,

510 
$$z \xrightarrow{d} N(\mu, 1)$$

511 
$$s = z^2 \xrightarrow{d} \chi_1^2 (\lambda)$$

512 In our previous study, we proved that the NCP parameter  $\lambda$  is a function of sample

513 size *N* and SNP effect size  $h^2$  [40]. Specifically,

$$\lambda = N imes \ln \left( rac{1}{1-h^2} 
ight) pprox Nh^2$$
 , for  $h^2 << 1$ 

514 , where ln() represents natural logarithm transformation, and  $h^2$  is the portion of phenotypic

515 variance explained by the SNP, e.g., the SNP-specific heritability. Specifically, we had

516 
$$h_X^2 = \frac{\operatorname{var}(\beta_1 G)}{\operatorname{var}(X)}$$
, and  $h_Y^2 = \frac{\operatorname{var}(r\beta_1 G)}{\operatorname{var}(Y)} = h_X^2 r^2$ 

517 , so that the mean parameters for *X* and *Y* have the following forms

518  

$$\mu_X = \sqrt{\lambda_X} = \sqrt{N_X h_X^2}$$
, and  $\mu_Y = \sqrt{N_Y h_Y^2} = \sqrt{\frac{N_Y}{N_X}} \times r \mu_X$ 

519 Clearly, the mean parameter  $\mu_Y$  is completely determined by  $\mu_X$  and their causal effect r.

520 In the above formula, the parameter  $\mu_X$  is unknown and could be estimated from the

521 GWAS summary statistics with the following formula

$$\hat{\mu}_X = \sqrt{\frac{N_X \hat{\beta}_1^2 \times 2f(1-f)}{\operatorname{var}(X)}}$$

522 , where *f* is minor allele frequency (MAF) of the IV. However, in practical released GWAS 523 summary statistics *X* may not be standardized so that its variance var(X) is unknown. In this 524 case, recall that

525 
$$p(z_X|\mu_X) = \frac{1}{\sqrt{2\pi}} e^{\frac{-(z_X - \mu_X)^2}{2}}.$$

526 Therefore, we replaced  $\mu_X$  by its maximum likelihood estimation, which is  $z_X$ , and re-wrote

527 the form of  $\mu_Y$ 

528 
$$\mu_Y = \sqrt{\frac{N_Y}{N_X}} \times r z_X = \Delta \tag{1}$$

Given  $\Delta$ , the probability of observing  $z_Y$  is simply the density of a normal distribution N( $\Delta$ , 1). Equivalently, if we let  $z'_Y = z_Y - \Delta$ , then  $z'_Y$  follows a standard normal distribution N(0, 1)

532 
$$z'_Y = z_Y - \Delta \xrightarrow{a} N(0,1)$$

# 533 Estimating *r* using *z*-scores

534 When multiple independent IVs are available, we built the estimation model within the 535 maximum likelihood framework. Assumed that there are a total of *M* independent IVs. Let

536 
$$z_X = (z_{X1}, z_{X2}, \dots, z_{XM})'$$
 and  $z_Y = (z_{Y1}, z_{Y2}, \dots, z_{YM})'$  be corresponding z-score vectors.

537 We constructed the likelihood function of r as

538 
$$L(r; \mathbf{z}_X, \mathbf{z}_Y, N_X, N_Y) = \prod_{m=1}^{M} p(z'_{Ym}).$$

539 Maximizing the likelihood function L(r) yielded the maximum likelihood estimate of r,

540 denoted by  $\hat{r}$ , and the maximum likelihood, denoted by  $L(\hat{r})$ .

541 The significance of  $\hat{r}$  was evaluated using the LRT approach. Specifically, by

restricting r=0, we obtained the null likelihood  $L_0$ . We then constructed the likelihood ratio

543 test statistic as follows

544 
$$T_1 = -2(\log(L_0) - \log(L(\hat{r}))).$$
(2)

545 Under the null hypothesis of r=0,  $T_1$  approximately follows a 1-df central chi-squared

546 distribution, which is used to judge the significance of 
$$\hat{r}$$
.

### 547 Modeling uncorrelated and correlated horizontal pleiotropy effects

548 We defined an IV to be valid if it has no horizontal pleiotropic effect. For a pleiotropic

549 IV, the estimator  $\hat{r}$  is not necessarily an unbiased estimator of r anymore. To see this, we

550 re-wrote the phenotype model for *Y* as

$$Y = rX + \beta_2 G + \varepsilon_Y$$
$$= (\beta_1 r + \beta_2)G + \varepsilon'_Y$$

551 , where  $\beta_2$  measures the pleiotropic effect of G on Y that is not mediated by X. In this

model,  $\hat{r}$  is an unbiased estimator of the following parameter instead

553 
$$E(\hat{r}) = E(\frac{\hat{\beta}_G^Y}{\hat{\beta}_1}) = r + \frac{\beta_2}{\beta_1}.$$

554 Depending on the direction of  $\beta_2$ ,  $\hat{r}$  could overestimate or underestimate the true effect *r*.

555 In the presence of pleiotropy, the association of *G* with *Y* is a mixture of the *X*-mediated

causal effect and the pleiotropic effect. Accordingly, the mean parameter  $\mu_Y$  is a mixture of

557 two components (Supplemental Notes)

$$\mu_Y = \Delta + \mu_P$$

558 so that

559 
$$z'_{Y} = (z_{Y} - \Delta) \xrightarrow{d} N(\mu_{P}, 1)$$
(3)

560 , where  $\mu_P^2 = N_Y h_P^2$  is a parameter defined by pleiotropy driven heritability

561 
$$h_P^2 = \frac{\operatorname{var}(\beta_2 G)}{\operatorname{var}(Y)}$$

In the above formula, the mean parameter 
$$\mu_Y$$
 is composed of two components: the  
first one is the causal effect, and the second one is the pleiotropic effect. The causal effect is  
fixed for not only valid IVs but also pleiotropic IVs. In contrast, the pleiotropic effect exists  
at pleiotropic IVs only and may vary depending on the strength of the IV-outcome effect,  
and was therefore modeled as a random effect. After removing the causal effect, the residual  
outcome z-score contains information about the pleiotropic effect only. Depending on  
whether it is correlated to  $z_X$  or not, the pleiotropic effect is further classified into two types.  
In the first type, the pleiotropic effect is directly on the outcome, so it is uncorrelated to  $z_X$ .  
In this case,  $\mu_P$  was modeled as a  $z_X$ -independent normally distributed effect

571 
$$\mu_{P_{unc}} = \mu_1 + \varepsilon_1, \qquad \varepsilon_1 \sim N(0, \sigma_{eu}^2).$$

572 In the second type, the pleiotropic effect is influenced by some unmeasured confounder 573 that is correlated to both the exposure and the outcome.  $\mu_P$  in this type is correlated to  $z_X$ 574 and the INSIDE assumption is violated [39]. Accordingly, it was modeled as a  $z_X$ -related 575 normally distributed effect

$$\mu_{P_{\text{cor}m}} = \mu_2 + a_m z_{Xm} + \varepsilon_2, \qquad \varepsilon_2 \sim N(0, \sigma_{ec}^2)$$

576 , where  $a_m$  measures the correlation between  $\mu_{P_{cor,m}}$  and  $z_{Xm}$  at the *m*th IV. We added the 577 subscript *m* in  $\mu_{P_{cor}}$  to emphasize that  $a_m$  is IV-specific whose magnitude depends on the 578 magnitude of the pleiotropy effect at the *m*th IV. To account for the variation of  $a_m$ , it was 579 further modeled as a normally distributed random effect

580 
$$a_m \sim N(\mu_a, \sigma_a^2)$$

581 where  $\mu_a$  and  $\sigma_a^2$  measure mean pleiotropic correlation and its variance, respectively.

582 Until now, we have built a hierarchical model towards the mean parameter of  $z'_Y$ 

583 distribution. We aimed to obtain its marginal distribution. To integrate out the intermediate

- 584 dummy variables, we introduced the following lemma,
- 585 Lemma I, If a random variable X follows a normal distribution  $X \sim N(\mu, \sigma_1^2)$ , and if its mean
- 586 parameter  $\mu$  is another random variable following a second normal distribution
- 587  $\mu \sim N(\mu_1, \sigma_2^2)$ , then the marginal distribution of X is again a normal distribution of the form
- 588  $X \sim N(\mu_1, \sigma_1^2 + \sigma_2^2)$  (Supplemental Notes).
- Applying this lemma, we first integrated out  $a_m$  to obtain the marginal distribution of  $\mu_{P_{cor}}$

590 
$$\mu_{Pcor} \sim N(\mu_2 + \mu_a z_X, z_X^2 \sigma_a^2 + \sigma_{ec}^2)$$

591 We then in turn integrated out  $\mu_{Punc}$  and  $\mu_{Pcor}$  to obtain the marginal distribution of  $z'_Y$ 

 $z'_{Y,\text{unc}} \sim N(\mu_1, 1 + \sigma_{eu}^2)$ 

592 and

593 
$$z'_{Y,cor} \sim N(\mu_2 + \mu_a z_X, 1 + z_X^2 \sigma_a^2 + \sigma_{ec}^2).$$

Taken together, for the three types of IVs (valid, uncorrelated pleiotropic and correlated pleiotropic), the residual z-score  $z'_{Y}$  after removing the causal effect *r* has a type-specific distribution

597 
$$z'_{Y} \sim \begin{cases} N(0,1), \text{ valid IV}; \\ N(\mu_{1}, 1 + \sigma_{eu}^{2}), \text{ uncorrelated pleiotropic IV}; \\ N(\mu_{2} + \mu_{a}z_{X}, 1 + z_{X}^{2}\sigma_{a}^{2} + \sigma_{ec}^{2}), \text{ correlated pleiotropic IV}. \end{cases}$$
(4)

One key inference from the above distributions is that  $z'_Y$  at different types has distinct variances. Specifically,  $z'_Y$  at valid IVs has an exact variance of one.  $z'_Y$  at pleiotropic IVs has a greater variance. This feature may make the three types of IVs distinguishable.

### 601 Likelihood function under horizontal pleiotropy

602 We assumed that the proportions of valid IVs, uncorrelated pleiotropic IVs and 603 correlated pleiotropic IVs are(1- $\tau$ ),  $\tau$ (1- $\rho$ ), and  $\tau\rho$ , where  $\tau$  and  $\rho \in [0,1]$  measure the

604 proportion of pleiotropic IVs and the relative proportion of correlated pleiotropic IVs,  
605 respectively. Our model contains nine parameters in total:  
606 
$$\boldsymbol{\theta} = (r, \mu_1, \mu_2, \mu_a, \sigma_a^2, \sigma_{eu}^2, \sigma_{ec}^2, \tau, \rho)$$
. We constructed a likelihood function of  $\boldsymbol{\theta}$  as follows  
607  $L(\boldsymbol{\theta}; \mathbf{z}_x, \mathbf{z}_y, N_x, N_y) = \prod_{m=1}^{M} \{(1 - \tau) P_{\text{valid}}(z'_{Ym}) + \tau(1 - \rho) P_{\text{unc}}(z'_{Ym} | \mu_1, \sigma_{eu}^2) + \tau \rho P_{\text{cor}}(z'_{Ym} | \mu_u, \mu_2, \sigma_{a}^2, \sigma_{ec}^2)\}$  (5)  
608 , where the probability densities were defined by equation (4).

609 Maximizing L regarding  $\theta$  yields the maximum likelihood estimate of  $\theta$ , denoted by 610  $\hat{\theta}$ , and the maximum likelihood, denoted by L( $\hat{\theta}$ ). We maximized L using the function *nmkb* 611 in the R package *dfoptim*, which implements a derivative-free Nelder–Mead algorithm for 612 high-dimensional function.

# 613 Test of causal effect

The causal effect is tested against the null hypothesis of r=0 by means of the LRT approach. Specifically, by restricting r=0 in (5), we constructed the null likelihood function, denoted by L<sub>0</sub>, which contains eight parameters. Maximizing L<sub>0</sub> over its sample space yields the maximum likelihood under the null hypothesis, denoted by L<sub>0</sub>( $\hat{\theta}_0$ ). The LRT statistic was then constructed as follows

619 
$$T_2 = -2(\log(L_0(\widehat{\theta}_0)) - \log(L(\widehat{\theta}))).$$
(6)

620 Under the null hypothesis of r=0,  $T_2$  approximately follows a 1-df central chi-squared 621 distribution, which was used to declare the significance of  $\hat{r}$ .

# 622 Test of pleiotropic effects

623 The existence of pleiotropic effects was tested against the null hypothesis of  $\tau$ =0 using 624 the same LRT approach. Under the null hypothesis, the likelihood function contains only one 625 free parameter *r*. Therefore, we used a 8-df central chi-squared distribution to declare the

626 significance of the estimate  $\hat{\tau}$ .

627 In implementation, we will first test pleiotropic effects at the significance level P < 0.05.

628 If there is evidence of pleiotropic effects, then we will use  $T_2$  to test the causal effect;

- 629 otherwise, we will use  $T_1$  instead.
- 630 Unstandardized phenotypes

Since  $\hat{r}$  is estimated based on z-scores, its test significance remains unchanged regardless of whether exposure or outcome is standardized. However, its magnitude may differ from the original effect size when unstandardized exposure or outcome is analyzed. The ratio of  $\hat{r}$  to the original effect size is a constant *C* that is determined by the unit of exposure and outcome under analysis. In certain scenarios, it is desirable to obtain the original effect size, such as to recover the odds ratio for case-control data types.

To recover the original effect size, we estimated *C* by anchoring our test to a comparable alternative test. As demonstrated in the Results section, our proposed test statistic  $T_1$ , which assumes no pleiotropic effects, yields an effect size approximately equal to the IVW test, which also assumes no pleiotropic effects. Consequently, we conducted both the  $T_1$  test and the IVW test on the same dataset and estimated *C* by calculating the ratio of their effect sizes.

#### 643 Simulation studies

We performed a series of simulation studies to evaluate the performance of the proposed method. We simulated one continuous exposure *X*, one continuous outcome *Y* and one continuous confounder *U*. We simulated a set of bi-allelic SNP as IVs for the exposure. We studied a two-sample context so that the exposure and outcome summary statistics were

648 generated from two separate samples. Parameter settings were as follows:

- 649 1) The number of IVs was set to be M=200.
- 650 2) Both exposure and outcome sample sizes were set to be  $N_X = N_Y = 200,000$ .
- 651 3) The causal effect of X on Y was set to be r=0 (null), 0.05 (positive effect), or -0.05
- (negative effect). In the latter two cases, X explained  $r^2=0.25\%$  of Y's variance.

4) Confounder effect. In the case of confounding effect, the effect of the confounder U was

set to explain 20% of phenotypic variance in both X and Y. The effect directions of U on

655 both *X* and *Y* were set to be the same.

657

656 5) Proportion of pleiotropic IVs to the outcome ( $\tau$ ). The proportion of pleiotropic IVs  $\tau$ 

varied from 10% to 60% at an increment of 10%. The default direction of the pleiotropic

effects was assumed to be positively dominated, in which 70% : 30% of pleiotropic IVs were simulated to have positive : negative pleiotropic effects. In the case of balanced pleiotropic effects, 50% : 50% of pleiotropic IVs were simulated to have positive : negative pleiotropic effects.

662 6) Relative proportion of correlated IVs ( $\rho$ ). From the pleiotropic IVs simulated in step 5), 663 a fraction of  $\rho = 0.5$  IVs were simulated to also have a pleiotropic effect on U. For ease of 664 presentation, the direction of the pleiotropic effects on U was set to be the same as that on Y. 665 7) IV effects on exposure. We assumed a non-infinitesimal genetic architecture for 666 IV-exposure effects. A proportion of 10% of total IVs were simulated to have a large effect 667 each explaining 0.2% of X's variance. The portion of explained variance for each of the 668 remaining 90% IVs was drawn from an exponential distribution with a mean  $1.0 \times 10^{-4}$ , a 669 level comparable to the majority of GWAS findings. The 200 IVs explained approximately a

# 670 total of 5.8% of X's variance.

671	8) IV pleiotropic effects on outcome and confounder. The portion of the variance in both $Y$
672	and $U$ explained by each pleiotropic IV was drawn from an exponential distribution with a
673	mean $1.0 \times 10^{-4}$ .
674	Each scenario was simulated with 1,000 iterations. At each simulation iteration, the
675	MAF of each IV was drawn from a uniform distribution <i>uni</i> (0.05, 0.5), and the IV genotypes
676	at both exposure and outcome samples were simulated using PLINK [59] assuming the
677	Hardy-Weinberger equilibrium. After the phenotypes were simulated, PLINK was invoked
678	to test genetic association in both the exposure and the outcome samples.

# 679 Comparison with existing methods

680 We evaluated and compared the performance of the proposed method with 14 existing 681 two-sample MR methods, including IVW [23], MREGGER [22], weighted-median 682 (W-median) [21], weighted-mode (W-mode) [20], MRPRESSO [19], the contamination 683 mixed model (CMix) [16], MRMix [18], MRAID [11], MRcML [12], GRAPPLE [13], 684 MRLASSO [17], MRRAPS [14], MRROBUST [17], and CAUSE [15]. Comparison criteria 685 included type-I error rate, power rate and estimated effect size. The statistical significance was declared at the nominal level  $\alpha$ =0.05. In power rate estimation, only effects in the same 686 687 direction as the true effect were considered as potentially successful hits. Effects in the 688 opposite direction were not considered regardless of their statistical significance.

Because various methods may possess different type-I error rates, comparing raw
power rates may be unfair. To ensure a fair comparison of power rates, the raw power rate
was corrected by calibrating it with the type-I error rate estimated at the corresponding null

# 692 condition. This correction was only for comparison purpose. It allows all methods to operate

under the assumption of possessing a correct type-I error rate of 0.05

694	Power <sub>cor</sub> =Power <sub>raw</sub> - type-I+0.05.
695	CAUSE requires a substantial number of background SNPs spanning the genome to
696	estimate its model parameters. To meet this requirement, we generated an additional random
697	set of 100,000 independent SNPs that are associated with neither the exposure nor the
698	outcome. This combination of 100,000 background SNPs and the IVs was used for
699	estimating nuisance parameters (step 1), while only the IVs were used for causal inference
700	(step 2). For all other methods, only the IVs were used for causal inference.
701	Due to their high computational demands, CAUSE and MRPRESSO were assessed
702	across 200 iterations.
703	Real data application
704	Lean body mass is an important physiological index. Low ALM, coupled with
704 705	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion
704 705 706	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion for the onset of sarcopenia [60], which is a critical condition that can significantly impair
704 705 706 707	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion for the onset of sarcopenia [60], which is a critical condition that can significantly impair function, lead to physical disability, and is a major modifiable risk factor for frailty in older
704 705 706 707 708	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion for the onset of sarcopenia [60], which is a critical condition that can significantly impair function, lead to physical disability, and is a major modifiable risk factor for frailty in older adults [61, 62]. Lipids are another cluster of metabolites related to energy balance [63, 64].
704 705 706 707 708 709	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion for the onset of sarcopenia [60], which is a critical condition that can significantly impair function, lead to physical disability, and is a major modifiable risk factor for frailty in older adults [61, 62]. Lipids are another cluster of metabolites related to energy balance [63, 64]. Disorders of lipid metabolism can co-occur with the loss of skeletal muscle mass [65, 66].
704 705 706 707 708 709 710	Lean body mass is an important physiological index. Low ALM, coupled with diminished muscle strength and reduced physical performance, serves as a defining criterion for the onset of sarcopenia [60], which is a critical condition that can significantly impair function, lead to physical disability, and is a major modifiable risk factor for frailty in older adults [61, 62]. Lipids are another cluster of metabolites related to energy balance [63, 64]. Disorders of lipid metabolism can co-occur with the loss of skeletal muscle mass [65, 66]. However, the mutual relationship between ALM and lipid traits has not been well-studied.

712 intervention of sarcopenia.



As a real application, we conducted a comprehensive bidirectional MR study between

ALM and four lipid traits, including HDL-C, LDL-C, TC, and TG using two data sources: the UKB internal cohort and the summary statistics released by GLGC. The study (project number 41542) was covered by general ethical approval for the UKB study, and was approved by the Northwest Centre for Research Ethics Committee (11/NW/0382). All participants provided informed consent.

719 The study design is displayed in Supplemental Figure 7. In brief, we performed both 720 the UKB-internal analysis and the UKB-GLGC joint analysis. In the UKB-internal analysis, 721 we randomly divided the entire UKB cohort into two independent sub-samples (UKB S1 722 and UKB\_S2). For each exposure-outcome pair (e.g., ALM-TC), one sub-sample served as 723 the exposure sample, while the other served as the outcome sample. This process was 724 repeated by reversing the roles of the two sub-samples so that two independent sets of 725 summary statistics were generated [41]. In the UKB-GLGC analysis, the whole UKB cohort 726 was used to generate GWAS summary statistics for ALM, while the GLGC data (excluding 727 UKB participants) provided summary statistics for the lipid traits. In total, for each 728 exposure-outcome pair, we generated three datasets that are mutually independent in 729 exposure and/or outcome, so that the results from them could cross-validate each other.

To evaluate the influence of sample overlap, we also applied a MR analysis in which both the exposure and the outcome summary statistics were derived from the whole UKB cohort, so that both samples completely overlapped.

The details of the analysis are described in **Supplemental Notes**. In brief, the GWAS of UKB samples was performed with BOLT-LMM [67]. Genome-wide significant (p< $5.0 \times 10^{-8}$ ) SNPs were selected from the exposure sample, followed by clumping (LD r<sup>2</sup>=0.01

736	and window size=500 kb) to select eligible IVs using TwoSampleMR R package. In the
737	UKB-GLGC joint analysis, GWAS of ALM was conducted in the whole UKB cohort, while
738	the GWAS summary statistics of lipid traits were derived from the released GLGC results
739	including no UKB participants. In the UKB-overlapping analysis, the GWAS summary
740	statistics of both ALM and lipid traits were derived from the whole UKB cohort. The QC
741	and MR analysis procedure are the same across various analyses. However, in analyses
742	using UKB samples only (UKB-internal and UKB-overlapping), palindromic IVs were not
743	excluded, while in the UKB-GLGC joint analysis, palindromic IVs were excluded to avoid
744	strand orientation error.

# 745 Mouse-model experiments

The experimental procedures and treatments conducted in this study were ethically
reviewed and approved by the Animal Care Ethical Committee of Soochow University,
Suzhou, China, ensuring compliance with animal welfare guidelines and regulations.

749 Male C57BL/6 mice, aged 8 weeks and weighing  $20 \pm 5$  g, were procured from 750 Shanghai Lingchang Biotechnology Co., LTD. These mice were housed in a controlled 751 environment with a temperature of  $23 \pm 1$  °C and a 12:12-hour light-dark cycle (lights on 752 from 07:00 to 19:00), and they had free access to food and water throughout the experiment. 753 Following a 1-week acclimatization period, the mice were randomly assigned to two 754 groups: the control group (N=12) and the TC group (N=12). Standard feed was obtained 755 from Double Lion Experimental Animal Feed Technology Co., LTD, Suzhou. The control 756 group received a standard diet consisting of 71% normal diet food, 20% protein, 4% fat, and 757 5% fiber. In contrast, the TC group received a high-cholesterol diet comprising 68.3%

normal diet food, 1.3% cholesterol, 18.4% lard, and 12% protein. This dietary interventioncontinued for a duration of 8 weeks.

760 Body composition analysis, including measurements of total body mass, fat mass, lean 761 mass, and fluid content, was conducted on live animals without the use of anesthesia. This 762 analysis was performed using small animal MRI equipment (Minispec LF50 body 763 composition analyzer, Bruker, Billerica, MA, USA). To conduct the measurements, each 764 mouse was placed in a specially designed plastic holder tailored for mice, without the need 765 for sedation or anesthesia. Subsequently, the holder containing the mouse was positioned 766 within the measuring space of the MRI system. To ensure the accuracy of the results, 767 measures were taken to prevent the mice from moving within the holder during the scanning 768 process. Each scan lasted approximately 2 minutes, during which the MRI equipment 769 captured detailed data on the body composition of the mice.

770 Blood biochemistry analysis was conducted using a Hitachi 7100 clinical chemistry 771 analyzer in accordance with the manufacturer's guidelines. Approximately 500  $\mu$ L of plasma 772 was collected from each mouse and transferred to a gel tube containing lithium heparin. 773 Subsequently, the plasma samples were centrifuged at 5000 rpm using a refrigerated 774 centrifuge set at  $4^{\circ}$ C for 15 minutes to obtain 160–200 µL of serum. In cases where the 775 volume of serum obtained was insufficient for analysis, it was diluted with deionized water 776 at a ratio of 1:2 to ensure proper loading for analysis. This process ensured accurate and 777 reliable blood biochemistry measurements for each sample.

37

- For each trait, the difference of measurement between the endpoint and the baseline
- 779 was analyzed. The comparison was made between the control group and the intervention
- 780 group using the Wilcoxon rank test in R package.

781	<b>Competing interests</b>
782	We declare that none of the authors have competing financial or non-financial interests.
783	Data availability
784	Access to UK Biobank data can be obtained by application to UK Biobank
785	(https://www.ukbiobank.ac.uk/).
786	Code availability
787	All analyses have been performed using publicly available software or custom codes.
788	PLINK (v1.90b6.5, https://www.cog-genomics.org/plink/) and BOLT-LMM (v2.3.2,
789	https://alkesgroup.broadinstitute.org/BOLT-LMM/) were used to perform association
790	analysis in the simulated data and in the UK Biobank data, respectively. The MR analyses
791	were performed using R (v.4.3.2, https://cran.r-project.org/). The R package TwoSampleMR
792	(v0.5.7, https://github.com/MRCIEU/TwoSampleMR) was used to implement the IVW,
793	MREGGER, W-median, and W-mode methods. MRAID
794	(https://github.com/yuanzhongshang/MRAID), CAUSE (v1.2.0,
795	https://github.com/jean997/cause), MRcML (https://github.com/xue-hr/MRcML/),
796	GRAPPLE (https://github.com/jingshuw/GRAPPLE), MRMix
797	(https://github.com/gqi/MRMix), mr.raps (https://github.com/qingyuanzhao/mr.raps),
798	MR-PRESSO (https://github.com/rondolab/MR-PRESSO) were used to implement
799	respective methods. MendelianRandomization (v0.9.0,
800	https://cran.r-project.org/web/packages/MendelianRandomization/index.html) was used to
801	implement the CMix, MRLASSO and MRROBUST methods [68]. The R package dfoptim
802	(v2023.1.0, https://cran.r-project.org/web/packages/dfoptim/index.html) was used to
803	optimize high-dimensional likelihood function.

-	-	-
0	1	л
0	υ	4

#### **Figure legends**

### 805 Figure 1. Diagram of the proposed method.

806	Four elements are involved: IV $G$ , exposure $X$ , outcome $Y$ , and confounder $U$ . $X$ and $Y$ are
807	represented by their association z-scores with $G$ . There are three potential pathways from $G$
808	to Y, depending on G's pleiotropic status: valid (purple), uncorrelated pleiotropic (blue) and
809	correlated pleiotropic (red). The causal effect $\Delta$ (green) exists in all pathways. After
810	removing the causal effect $\Delta$ from $z_Y$ (lower panel), the residual outcome z-score $z'_Y$
811	contains information on pleiotropic effects only. Depending on in which pathway G is, $z'_Y$
812	has a pathway-specific distribution (right panel), which is used to differentiate valid and
813	pleiotropic IVs.

### 814 Figure 2. The distribution of outcome z-scores at valid and pleiotropic IVs.

815 The influence of three factors on the distribution of outcome z-score was evaluated: outcome 816 sample size ( $N_Y$ =1e5 or 2e5), the variance of IV-specific heritability to the outcome ( $\sigma_b^2$ ), 817 and the proportion of positive pleiotropic IVs (fp=0.5, 0.7 or 1.0). The IV-specific heritability  $\square_Y^2$  was drawn from an exponential distribution with a mean 5e-5 or 1e-4 so 818 that its variance  $\sigma_h^2 = (5e-5)^2$  or  $(1e-4)^2$ . The exposure sample size was set to be  $N_X = 2e5$ . The 819 820 causal effect of X on Y was set to be r=0.05.  $z_Y$  is IV-outcome z-score.  $z'_Y$  is the residual of  $z_Y$  after removing the causal effect. var $(z'_{Y,\text{theo}})$  is the theoretical variance assuming fp=1.0. 821 822 At valid IVs, both  $z_Y$  and  $z'_Y$  conform to a standard normal distribution. At pleiotropic IVs, the variance of  $z'_Y$  exceeds one and escalates with increasing  $N_Y$  and/or  $\sigma_h^2$ . When  $f_p=1.0$ , 823 the variance of  $z'_{Y}$  aligns well with  $var(z'_{Y,theo})$ , and amplifies when  $f_{p}<1.0$ , peaking when 824

the positive and negative pleiotropic IVs are evenly balanced ( $f_p=0.5$ ).  $z_Y$  has a similar

826 distribution to  $z'_Y$ .

#### 827 Figure 3. The performance of MRZ in detecting pleiotropic effects.

828 A total of 200 IVs and 1000 iterations were simulated. A, The proportion of pleiotropic IVs 829 ranges from 10%-60%. The relative proportion of correlated pleiotropic IVs is 50%. The 830 power of detecting pleiotropy was declared at  $\alpha = 0.05$  level. **B**, Presented is the mean 831 estimated proportion of pleiotropic IVs. Error bar is its standard deviation. Four scenarios 832 were simulated, correlated pleiotropic effects and no causal effect (correlated\_null), 833 correlated pleiotropic effects and causal effect (correlated\_causal), uncorrelated pleiotropic 834 effects and no causal effect (uncorrelated null), and uncorrelated pleiotropic effects and 835 causal effect (uncorrelated causal). C, In this simulation, the proportion of pleiotropic IVs 836 was fixed at 60%, while the relative proportion of correlated pleiotropic IVs ranges from 837 10%-60%. Both causal and null scenarios were simulated. Presented is the mean estimated proportion of correlated pleiotropic IVs. The error bar is its standard deviation. D, the per-IV 838 839 correlated pleiotropic effect was defined as the product of the proportion of correlated 840 pleiotropic IVs and the mean correlated pleiotropic effect. The IV-specific heritability to the 841 confounder was drawn from an exponential distribution with a mean 1e-4, 5e-5, or 0, 842 respectively. These different settings correspond to different magnitudes of correlated 843 pleiotropic effects.

### 844 Figure 4. Corrected power rate of various methods for testing causal effect.

845 A total of 200 IVs were simulated. The sample sizes for both exposure and outcome samples

846	were 2e5. The 200 IVs explained approximately a portion of 5.8% of the exposure variance.
847	A positively dominated pleiotropic setting was simulated, in which 70% pleiotropic IVs
848	were simulated to have positive pleiotropic effects while the remaining 30% were simulated
849	to have negative pleiotropic effects. In addition, half pleiotropic IVs were simulated to be
850	correlated with the corresponding IV-exposure effects. The causal effect $r$ was set to be 0.05
851	(positive effect) or -0.05 (negative effect). The statistical significance was declared at
852	$\alpha = 0.05$ level. Raw power rate was corrected by calibrating it with the type-I error rate
853	estimated at the corresponding null condition, using the equation

 $Power_{cor} = Power_{raw} - type - I + 0.05.$ 854

#### 855 Figure 5. Estimated causal effect size of various methods.

856 The causal effect r was set to be 0.05 (positive effect) or -0.05 (negative effect). The mean

857 effect size across 1,000 iterations is presented.

#### 858 Figure 6. The randomized controlled experiment intervened by TC in mice.

859 Male C57BL/6 mice were randomly allocated to control group (N=12) and intervention 860 group (N=12), followed by intervention by TC diet in the TC group for 8 weeks. For each 861 trait, the difference of measurement between the endpoint and the baseline was analyzed. 862 The comparison was made between the control group and the intervention group using the 863 Wilcoxon rank test. \*\*\*, P<0.001; \*\*, P<0.001; NS, non-significant (P>0.05).

	r=0.00		r=0.05	
Method	Type-I error	Power	Effect	ME
MRZ	0.052	0.999	0.049	0.008
CAUSE	0.001	0.800	0.050	0.008
W-mode	0.002	0.104	0.050	0.033
MREGGER	0.049	0.950	0.049	0.011
MRMix	0.068	0.259	0.049	0.025
IVW	0.065	0.999	0.049	0.008
W-median	0.031	0.948	0.049	0.010
GRAPPLE	0.056	0.999	0.050	0.008
MRcML	0.067	0.999	0.050	0.008
RAPS	0.057	0.999	0.050	0.008
MRROBUST	0.061	0.999	0.049	0.008
MRLASSO	0.073	0.998	0.049	0.008
CMix	0.054	0.998	0.049	0.008
MRPRESSO	0.050	0.998	0.049	0.008
MRAID	0.047	0.997	0.049	0.008

### Table 1, Performance of various methods with all valid IVs.

864

Notes: A total of 1,000 iterations were simulated. In each iteration, the sample size for both exposure and outcome samples was set to be 200,000. A total of 200 IVs were simulated, all of which are valid having no pleiotropic effect on the outcome. The 200 IVs explain approximately a portion of 5.8% of the exposure variance. Causal effect size was set to be r=0.00 (null) or r=0.05 (causal). Effect, mean estimated effect size across the 1,000 iterations; ME, mean error, defined as the absolute error of the estimated effect size from the true effect size r=0.05.

Table 2, Type-I error rates of various methods under pleiotropic effects.															
PleiotropicIVs(%)	MRZ	CAUSE	W-mode	EGGER	MRMix	MRAID	IVW	W-median	CMix	GRAPPLE	MRcML	MRROBUST	MRLASSO	RAPS	MRPRESSC
							Uncorre	lated pleiotropy	7						
10	0.05	0.00	0.00	0.06	0.03	0.06	0.15	0.05	0.07	0.04	0.12	0.08	0.10	0.08	0.08
20	0.04	0.00	0.00	0.06	0.06	0.08	0.30	0.07	0.12	0.13	0.26	0.12	0.16	0.16	0.19
30	0.04	0.00	0.00	0.05	0.05	0.14	0.47	0.12	0.24	0.31	0.42	0.24	0.30	0.31	0.49
40	0.07	0.01	0.01	0.06	0.09	0.22	0.60	0.21	0.40	0.54	0.61	0.47	0.51	0.50	0.66
50	0.05	0.01	0.01	0.06	0.10	0.31	0.69	0.30	0.53	0.68	0.75	0.69	0.71	0.61	0.83
60	0.04	0.02	0.01	0.05	0.22	0.44	0.77	0.45	0.73	0.81	0.87	0.83	0.89	0.73	0.92
							Correla	ated pleiotropy							
10	0.03	0.00	0.00	0.10	0.02	0.04	0.32	0.03	0.05	0.03	0.10	0.05	0.07	0.06	0.11
20	0.06	0.00	0.00	0.12	0.04	0.08	0.62	0.08	0.12	0.25	0.21	0.11	0.19	0.20	0.25
30	0.05	0.01	0.00	0.16	0.05	0.10	0.81	0.17	0.20	0.62	0.39	0.24	0.38	0.51	0.69
40	0.04	0.01	0.01	0.20	0.05	0.15	0.93	0.30	0.34	0.87	0.57	0.59	0.67	0.82	0.91
50	0.05	0.02	0.01	0.24	0.08	0.25	0.98	0.49	0.54	0.97	0.74	0.93	0.89	0.94	0.95
60	0.05	0.02	0.03	0.28	0.18	0.40	0.99	0.67	0.70	0.99	0.88	0.98	0.97	0.98	1.00

Notes: A total of 200 IVs and 1,000 iterations were simulated. Sample size for both exposure and outcome samples was set to be 2e5. The 200 IVs explain approximately a portion of 5.8% of the exposure variance. In the case of uncorrelated pleiotropy, 70% of all pleiotropic IVs were randomly selected to have positive pleiotropic effects while the remaining 30% pleiotropic IVs were simulated to have negative pleiotropic effects. In the case of correlated pleiotropy, 50% of pleiotropic IVs were simulated to be correlated with the corresponding IV-exposure effects. The causal effect r was set to be 0. The significance threshold was set to 0.05.

8		Table 3, B	idirect	tional o	causal	effects	of ALN	I and li	pid traits ide	entified l	by MRZ	Ζ.						
	Forward (ALM->lipids)									Reverse (lipids->ALM)								
Trait	Samples	Ν	IVs	$R^2$	F	$f_{pleio}$	r	SE	Р	IVs	$R^2$	F	$f_{pleio}$	r	SE	Р		
TC																		
	UKB_S1/UKB_S2	220K/216K	268	0.06	52.5	0.32	-0.08	0.02	3.65E-6	100	0.06	131.6	0.69	-0.05	0.04	0.22		
	UKB_S2/UKB_S1	220K/216K	261	0.06	52.3	0.33	-0.08	0.02	1.01E-6	115	0.06	112.9	0.77	-0.07	0.03	0.03		
	UKB/GLGC	440K/912K	716	0.09	64.3	0.61	-0.07	0.01	3.64E-7	497	0.09	175.1	0.88	-0.05	0.02	0.02		
LDL-C																		
	UKB_S1/UKB_S2	220K/216K	268	0.06	52.5	0.37	-0.05	0.02	2.67E-3	85	0.05	139.6	0.74	-0.06	0.04	0.13		
	UKB_S2/UKB_S1	220K/216K	261	0.06	52.3	0.46	-0.06	0.02	3.54E-4	92	0.05	129.0	0.63	-0.06	0.03	0.05		
	UKB/GLGC	440K/825K	718	0.10	64.4	0.56	-0.04	0.01	4.97E-3	397	0.08	188.8	0.66	-0.04	0.02	0.01		
TG																		
	UKB_S1/UKB_S2	220K/208K	267	0.06	52.4	0.56	0.01	0.03	0.75	109	0.05	107.6	0.66	0.03	0.02	0.15		
	UKB_S2/UKB_S1	220K/209K	260	0.06	52.1	0.53	-0.02	0.02	0.33	113	0.05	103.4	1.00	-0.05	0.04	0.28		
	UKB/GLGC	440K/849K	715	0.09	64.3	1.00	-0.03	0.05	0.49	461	0.07	148.1	1.00	-0.04	0.03	0.23		
HDL-C																		
	UKB_S1/UKB_S2	220K/196K	268	0.06	52.5	0.71	-0.01	0.04	0.78	191	0.10	110.0	0.69	-0.03	0.02	0.21		
	UKB_S2/UKB_S1	220K/196K	261	0.06	52.3	0.77	-0.03	0.04	0.46	197	0.09	103.0	0.73	-0.03	0.02	0.16		
	UKB/GLGC	440K/874K	719	0.10	64.5	0.98	-0.04	0.07	0.53	565	0.09	153.4	0.85	0.02	0.02	0.49		

879 Notes: The entire UKB cohort was randomly divided into two independent sub-samples (UKB\_S1 and UKB\_S2). For the UKB-internal analysis, the two

sub-samples were used as exposure and outcome samples, respectively. For the UKB-GLGC joint analysis, the entire UKB sample was used for ALM, while

881 GLGC summary statistics were used for lipid traits. For each ALM-lipid pair, three datasets were analyzed. TC, total cholesterol; LDL-C, low-density



883 K represents kilo; IVs, the number of IVs;  $R^2$ , the portion of exposure variance explained by all IVs; F, F-statistic;  $f_{pleio}$ , the estimated proportion of

pleiotropic IVs; r, estimated causal effect; P, p-value. The significance threshold was set at  $6.25 \times 10^{-3}$  (0.05/8). Significant associations were marked in bold.

885	Acknowledgments
886	This research was conducted using the UK Biobank resource under application number
887	41542. Special thank was given to an anonymous reviewer whose constructive comments
888	advised us to model correlated pleiotropic effects. This study was partially supported by the
889	funding from National Natural Science Foundation of China (32170670 to YFP, 81902181 to
890	JJN), the Project of MOE Key Laboratory of Geriatric Diseases and Immunology
891	(JYN202401 to HGR), and Suzhou Basic Research Program (Medical Application Basic
892	Research) (SKY2023147 to JJN).
893	

894	References
895	1. Smith, G.D. and S. Ebrahim, 'Mendelian randomization': can genetic epidemiology contribute to
896	understanding environmental determinants of disease? Int J Epidemiol, 2003. <b>32</b> (1): p. 1-22.
897	2. Burgess, S., et al., Use of Mendelian randomisation to assess potential benefit of clinical
898	<i>intervention</i> . BMJ, 2012. <b>345</b> : p. e7325.
899	3. Burgess, S., et al., Guidelines for performing Mendelian randomization investigations: update
900	<i>for summer 2023.</i> Wellcome Open Res, 2019. <b>4</b> : p. 186.
901	4. Yengo, L., et al., A saturated map of common genetic variants associated with human height.
902	Nature, 2022. <b>610</b> (7933): p. 704-712.
903	5. Solovieff, N., et al., <i>Pleiotropy in complex traits: challenges and strategies.</i> Nat Rev Genet, 2013.
904	<b>14</b> (7): p. 483-95.
905	6. Ebrahim, S. and G. Davey Smith, Mendelian randomization: can genetic epidemiology help
906	redress the failures of observational epidemiology? Hum Genet, 2008. <b>123</b> (1): p. 15-33.
907	7. Hemani, G., J. Bowden, and G. Davey Smith, Evaluating the potential role of pleiotropy in
908	Mendelian randomization studies. Hum Mol Genet, 2018. 27(R2): p. R195-R208.
909	8. Holmes, M.V., M. Ala-Korpela, and G.D. Smith, Mendelian randomization in cardiometabolic
910	disease: challenges in evaluating causality. Nat Rev Cardiol, 2017. <b>14</b> (10): p. 577-590.
911	9. Sanderson, E., et al., <i>Mendelian randomization</i> . Nat Rev Methods Primers, 2022. <b>2</b> .
912	10. Slob, E.A.W. and S. Burgess, A comparison of robust Mendelian randomization methods using
913	<i>summary data.</i> Genet Epidemiol, 2020. <b>44</b> (4): p. 313-329.
914	11. Yuan, Z., et al., Likelihood-based Mendelian randomization analysis with automated instrument
915	selection and horizontal pleiotropic modeling. Sci Adv, 2022. <b>8</b> (9): p. eabl5744.
916	12. Xue, H., X. Shen, and W. Pan, Constrained maximum likelihood-based Mendelian randomization
917	robust to both correlated and uncorrelated pleiotropic effects. Am J Hum Genet, 2021. 108(7): p.
918	1251-1269.
919	13. Wang, J., et al., Causal inference for heritable phenotypic risk factors using heterogeneous
920	genetic instruments. PLoS Genet, 2021. <b>17(</b> 6): p. e1009575.
921	14. Zhao, Q., et al., Statistical Inference in two-sample summary-data Mendelian randomization
922	using robust adjusted profile score. The Annals of Statistics, 2020. <b>48</b> (3): p. 1742-1769.
923	15. Morrison, J., et al., Mendelian randomization accounting for correlated and uncorrelated
924	pleiotropic effects using genome-wide summary statistics. Nat Genet, 2020. <b>52</b> (7): p. 740-747.
925	16. Burgess, S., et al., A robust and efficient method for Mendelian randomization with hundreds of
926	<i>genetic variants</i> . Nat Commun, 2020. <b>11</b> (1): p. 376.
927	17. Rees, J.M.B., et al., Robust methods in Mendelian randomization via penalization of
928	heterogeneous causal estimates. PLoS One, 2019. <b>14</b> (9): p. e0222362.
929	18. Qi, G. and N. Chatterjee, Mendelian randomization analysis using mixture models for robust and
930	<i>efficient estimation of causal effects.</i> Nat Commun, 2019. <b>10</b> (1): p. 1941.
931	19. Verbanck, M., et al., Detection of widespread horizontal pleiotropy in causal relationships
932	inferred from Mendelian randomization between complex traits and diseases. Nat Genet, 2018. 50(5):
933	p. 693-698.
934	20. Hartwig, F.P., G. Davey Smith, and J. Bowden, Robust inference in summary data Mendelian
935	randomization via the zero modal pleiotropy assumption. Int J Epidemiol, 2017. <b>46</b> (6): p. 1985-1998.
936	21. Bowden, J., et al., Consistent Estimation in Mendelian Randomization with Some Invalid

937 Instruments Using a Weighted Median Estimator. Genet Epidemiol, 2016. 40(4): p. 304-14.

938 22. Bowden, J., G. Davey Smith, and S. Burgess, Mendelian randomization with invalid instruments:

- 939 effect estimation and bias detection through Egger regression. Int J Epidemiol, 2015. 44(2): p.
  940 512-25.
- Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian randomization analysis with multiple genetic variants using summarized data*. Genet Epidemiol, 2013. 37(7): p. 658-65.
- 943 24. Jiang, L., et al., Constrained instruments and their application to Mendelian randomization with

944 *pleiotropy.* Genet Epidemiol, 2019. **43**(4): p. 373-401.

- 25. Cho, Y., et al., *Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian*randomization framework. Nat Commun, 2020. 11(1): p. 1010.
- 947 26. Sanderson, E., et al., An examination of multivariable Mendelian randomization in the
  948 single-sample and two-sample summary data settings. Int J Epidemiol, 2019. 48(3): p. 713-727.
- 949 27. Burgess, S. and S.G. Thompson, *Multivariable Mendelian randomization: the use of pleiotropic*950 genetic variants to estimate causal effects. Am J Epidemiol, 2015. **181**(4): p. 251-60.
- 28. Zhu, Z., et al., Causal associations between risk factors and common diseases inferred from
  GWAS summary data. Nat Commun, 2018. 9(1): p. 224.
- 953 29. Bowden, J., et al., Improving the accuracy of two-sample summary-data Mendelian
  954 randomization: moving beyond the NOME assumption. Int J Epidemiol, 2019. 48(3): p. 728-742.
- 955 30. Foley, C.N., et al., *MR-Clust: clustering of genetic variants in Mendelian randomization with*956 *similar causal estimates.* Bioinformatics, 2021. **37**(4): p. 531-541.
- 957 31. Berzuini, C., et al., A Bayesian approach to Mendelian randomization with multiple pleiotropic
  958 variants. Biostatistics, 2020. 21(1): p. 86-101.
- 32. Xu, S., W.K. Fung, and Z. Liu, *MRCIP: a robust Mendelian randomization method accounting for correlated and idiosyncratic pleiotropy.* Brief Bioinform, 2021. 22(5).
- 961 33. Cheng, Q., et al., MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics
- accounting for linkage disequilibrium and horizontal pleiotropy. NAR Genom Bioinform, 2020. 2(2): p.
  lqaa028.
- 34. Zhu, X., et al., An iterative approach to detect pleiotropy and perform Mendelian Randomization
  analysis using GWAS summary statistics. Bioinformatics, 2021. 37(10): p. 1390-1400.
- 966 35. Grant, A.J. and S. Burgess, An efficient and robust approach to Mendelian randomization with
   967 measured pleiotropic effects in a high-dimensional setting. Biostatistics, 2022. 23(2): p. 609-625.
- 968 36. Howey, R., et al., Bayesian network analysis incorporating genetic anchors complements
  969 conventional Mendelian randomization approaches for exploratory analysis of causal relationships in
  970 complex data. PLoS Genet, 2020. 16(3): p. e1008198.
- 971 37. long, D., Q. Zhao, and Y. Chen, A latent mixture model for heterogeneous causal mechanisms in
  972 Mendelian randomization. The Annals of Applied Statistics, 2024. 18(2): p. 966-990.
- 973 38. Graham, S.E., et al., *The power of genetic diversity in genome-wide association studies of lipids.*974 Nature, 2021. 600(7890): p. 675-679.
- 975 39. Burgess, S. and S.G. Thompson, Interpreting findings from Mendelian randomization using the
  976 MR-Egger method. Eur J Epidemiol, 2017. 32(5): p. 377-389.
- 977 40. Zhang, L., et al., A new method for estimating effect size distribution and heritability from
  978 genome-wide association summary results. Hum Genet, 2016. 135(2): p. 171-84.
- 979 41. Denault, W.R.P., et al., Cross-fitted instrument: A blueprint for one-sample Mendelian
  980 randomization. PLoS Comput Biol, 2022. 18(8): p. e1010268.

- 981 42. Watanabe, K., et al., A global overview of pleiotropy and genetic architecture in complex traits.
- 982 Nat Genet, 2019. 51(9): p. 1339-1348.
- 983 43. Frontera, W.R. and J. Ochala, *Skeletal muscle: a brief review of structure and function*. Calcif
  984 Tissue Int, 2015. 96(3): p. 183-95.
- 985 44. Zurlo, F., et al., Skeletal muscle metabolism is a major determinant of resting energy expenditure.
  986 J Clin Invest, 1990. 86(5): p. 1423-7.
- 45. Havel, P.J., Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid
  metabolism. Diabetes, 2004. 53 Suppl 1: p. S143-51.
- 989 46. Vella, C.A., et al., Skeletal muscle area and density are associated with lipid and lipoprotein
  990 cholesterol levels: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol, 2020. 14(1): p. 143-153.
- 991 47. Pickrell, J.K., et al., *Detection and interpretation of shared genetic influences on 42 human traits.*992 Nat Genet, 2016. 48(7): p. 709-17.
- 48. Luke, A. and D.A. Schoeller, Basal metabolic rate, fat-free mass, and body cell mass during
  energy restriction. Metabolism, 1992. 41(4): p. 450-6.
- 995 49. Johnstone, A.M., et al., Factors influencing variation in basal metabolic rate include fat-free
- 996 mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am J
  997 Clin Nutr, 2005. 82(5): p. 941-8.
- 998 50. Merz, K.E. and D.C. Thurmond, *Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake.*999 Compr Physiol, 2020. 10(3): p. 785-809.
- 1000 51. Hirano, T., *Pathophysiology of Diabetic Dyslipidemia*. J Atheroscler Thromb, 2018. 25(9): p.
  1001 771-782.
- 1002 52. Welc, S.S. and T.L. Clanton, The regulation of interleukin-6 implicates skeletal muscle as an
   1003 integrative stress sensor and endocrine organ. Exp Physiol, 2013. 98(2): p. 359-71.
- 1004 53. Brenmoehl, J., et al., Irisin is elevated in skeletal muscle and serum of mice immediately after
  1005 acute exercise. Int J Biol Sci, 2014. 10(3): p. 338-49.
- 1006 54. Nakagomi, A., et al., Relationships between the serum cholesterol levels, production of
   1007 monocyte proinflammatory cytokines and long-term prognosis in patients with chronic heart failure.
- 1008 Intern Med, 2014. **53**(21): p. 2415-24.
- 1009 55. Hardardottir, I., C. Grunfeld, and K.R. Feingold, *Effects of endotoxin and cytokines on lipid* 1010 *metabolism.* Curr Opin Lipidol, 1994. 5(3): p. 207-15.
- 1011 56. Burgess, S., N.M. Davies, and S.G. Thompson, *Bias due to participant overlap in two-sample* 1012 *Mendelian randomization.* Genet Epidemiol, 2016. 40(7): p. 597-608.
- 1013 57. Jiang, T., et al., An empirical investigation into the impact of winner's curse on estimates from
   1014 Mendelian randomization. Int J Epidemiol, 2023. 52(4): p. 1209-1219.
- 1015 58. Winkler, T.W., et al., Quality control and conduct of genome-wide association meta-analyses.
  1016 Nat Protoc, 2014. 9(5): p. 1192-212.
- 1017 59. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage*1018 *analyses.* Am J Hum Genet, 2007. 81(3): p. 559-75.
- 1019 60. Cruz-Jentoft, A.J., et al., Sarcopenia: revised European consensus on definition and diagnosis.
  1020 Age Ageing, 2019. 48(1): p. 16-31.
- 1021 61. Giles, J.T., et al., Association of body composition with disability in rheumatoid arthritis: impact
- 1022 of appendicular fat and lean tissue mass. Arthritis Rheum, 2008. 59(10): p. 1407-15.
- 1023 62. Janssen, I., S.B. Heymsfield, and R. Ross, Low relative skeletal muscle mass (sarcopenia) in older
- 1024 persons is associated with functional impairment and physical disability. J Am Geriatr Soc, 2002.

- 1026 63. Arner, P., et al., Dynamics of human adipose lipid turnover in health and metabolic disease.
- 1027 Nature, 2011. 478(7367): p. 110-3.
- 1028 64. Arner, P., et al., Adipose lipid turnover and long-term changes in body weight. Nat Med, 2019.
- 1029 **25**(9): p. 1385-1389.
- 1030 65. Jiang, Y., et al., The association of lipid metabolism and sarcopenia among older patients: a
- 1031 *cross-sectional study.* Sci Rep, 2023. **13**(1): p. 17538.
- 1032 66. Kim, G. and J.H. Kim, *Impact of Skeletal Muscle Mass on Metabolic Health*. Endocrinol Metab
  1033 (Seoul), 2020. 35(1): p. 1-6.
- 1034 67. Loh, P.R., et al., *Efficient Bayesian mixed-model analysis increases association power in large* 1035 *cohorts.* Nat Genet, 2015. **47**(3): p. 284-90.
- 1036 68. Yavorska, O.O. and S. Burgess, MendelianRandomization: an R package for performing
- 1037 *Mendelian randomization analyses using summarized data.* Int J Epidemiol, 2017. **46**(6): p. 1038 1734-1739.

1039

<sup>1025</sup> **50**(5): p. 889-96.











